Rune Labs Partners with Coastal Research Institute to Identify Biomarkers of Multiple Sclerosis Lesions using AI Platform to Analyze Patient Neurophysiological Data
SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine.
- The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology.
- Clinical scores currently used as endpoints and screeners in trials are imprecise and do not always correlate with lesion activity.
- "Rune's AI platform enables us to take raw brain data and convert it into actionable biomarkers of myelination."
- Rune Labs' first-in-class precision neurology software platform uses machine learning to capture and analyze electrophysiological brain data to uncover previously overlooked markers of disease.